Belite Bio (BLTE) Non Operating Income (2022 - 2026)
Belite Bio (BLTE) posted quarterly Non Operating Income of $5.7 million for Q1 2026, up 363.39% year-over-year from $1.2 million in Q1 2025, and down 99.79% quarter-over-quarter from $2.8 billion in Q4 2025.
Belite Bio (BLTE) Non Operating Income (2022 - 2026) Analysis & Trends
Belite Bio's Non Operating Income history runs 5 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 363.39% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.4 billion (up 57.9% YoY), while the FY2025 annual figure was $6.6 million, up 71.0% from the prior year.
- Non Operating Income for Q1 2026 stood at $5.7 million, down from $2.8 billion in the prior quarter.
- The five-year high for Non Operating Income was $2.8 billion in Q4 2025, with the low at -$8.0 million in Q1 2023.
- The 5-year median for Non Operating Income is $126.0 million (2022), against an average of $595.5 million.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income tumbled 99.98% in 2023, then soared 3929529.63% in 2024.
- Belite Bio's Non Operating Income stood at -$62000.0 in 2022, then jumped by 41.94% to -$36000.0 in 2023, then soared by 3769544.44% to $1.4 billion in 2024, then surged by 102.87% to $2.8 billion in 2025, then sank by 99.79% to $5.7 million in 2026.
- Business Quant data shows BLTE's Non Operating Income at $5.7 million in Q1 2026, $2.8 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 5.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.75 Mn |
| Dec 31, 2025 | 2.75 Bn |
| Sep 30, 2025 | 1.33 Bn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.36 Bn |
| Sep 30, 2024 | 1.06 Bn |
| Jun 30, 2024 | 977.00 Mn |
| Mar 31, 2024 | 463.00 Mn |
| Dec 31, 2023 | -36,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Jun 30, 2023 | 62.00 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Dec 31, 2022 | -62,000.00 |
| Sep 30, 2022 | 137.00 Mn |
| Jun 30, 2022 | 115.00 Mn |